New PET scan agent could spot rare heart disease faster

NCT ID NCT06788535

Completed Diagnosis Sponsor: Sharmila Dorbala Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new imaging drug called I-124 evuzamitide to see if it can accurately diagnose cardiac amyloidosis, a condition where abnormal proteins build up in the heart. 204 adults with suspected cardiac amyloidosis received a single dose followed by a PET/CT scan. The goal was to check if the scan correctly identifies the disease (sensitivity) and rules it out when absent (specificity).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC AMYLOIDOSIS

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
City of Hope - Duarte

Duarte, California, 91010, United States
Cleveland Clinic

Weston, Florida, 33331, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Columbia University

New York, New York, 10032, United States
Cone Health

Greensboro, North Carolina, 27401, United States
Cook County Health

Chicago, Illinois, 60612, United States
Duke University

Durham, North Carolina, 27710, United States
Houston Methodist

Houston, Texas, 77030, United States
Mayo Clinic

Scottsdale, Arizona, 85259, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Northwestern University

Chicago, Illinois, 60611, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Rutgers

New Brunswick, New Jersey, 08901, United States
St. Lukes (CVIT) Saint Luke's Health System

Kansas City, Missouri, 64111, United States
University of California

San Francisco, California, 94143, United States
Washington University of St. Louis

St Louis, Missouri, 63110, United States
Yale Cardiovascular Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.